125328-80-5

Usage

Uses

Used in Chemical Synthesis:
N-(4-BROMO-3-CHLORO-2-METHYL-PHENYL) ACETAMIDE is used as a reagent for the synthesis of indoxyl-glycosides. These indoxyl-glycosides are essential in the monitoring of glycosidase activities, which are crucial enzymes involved in the metabolism of carbohydrates. The compound plays a vital role in the development of assays and diagnostic tools for studying the function and regulation of these enzymes.
Used in Pharmaceutical Research:
In the pharmaceutical industry, N-(4-BROMO-3-CHLORO-2-METHYL-PHENYL) ACETAMIDE may be utilized as a building block or intermediate in the development of new drugs. Its unique structure and functional groups can be exploited to create novel compounds with potential therapeutic applications. Researchers can use N-(4-BROMO-3-CHLORO-2-METHYL-PHENYL) ACETAMIDE to explore its interactions with various biological targets, such as proteins or enzymes, which could lead to the discovery of new drugs for treating various diseases.
Used in Material Science:
The compound's structural features and chemical properties may also make it a candidate for use in material science applications. It could potentially be incorporated into the development of new materials with specific properties, such as improved stability, reactivity, or selectivity in certain chemical processes. This could have implications for various industries, including electronics, coatings, and adhesives.

InChI:InChI=1/C9H9BrClNO/c1-5-8(12-6(2)13)4-3-7(10)9(5)11/h3-4H,1-2H3,(H,12,13)

Upstream product

• 87-60-5 3-chloro-2-methylbenzenamine 
• 627531-47-9 4-amino-2-chloro-3-methylbromobenzene 
• 108-24-7 acetic anhydride 
• 7463-35-6 N-(3-chloro-2-methylphenyl)acetamide 
• 7726-95-6 bromine 
• 98-95-3 nitrobenzene 

Downstream Products

• 627531-48-0 N-(3-chloro-4-cyano-2-methylphenyl)acetamide 
• 573768-09-9 4-amino-2-chloro-3-methyl-benzonitrile 
• 1447125-25-8 C₁₅H₁₅BrClNO₄ 
• 125328-84-9 (5-Bromo-4-chloro-indol-3-yl)-β-L-fucopyranoside 
• 153248-52-3 5-bromo-4-chloro-indol-3-yl-(5-acetamido-3,5-dideoxy-α-D-glycero-D-galacto-2-nonulopyranosylonic acid) 
• 125328-77-0 N-acetyl-5-bromo-6-chloroanthranilic acid 
• 3030-19-1 2-amino-5-bromo-6-chlorobenzoic acid 
• 864361-83-1 4-((7S)-7-(tert-butyldimethylsilyloxy)-1-methyl-3-oxo-5,6,7,7a-tetrahydro-3H-pyrrolizin-2-yl)-2-chloro-3-methylbenzonitrile 
• 864361-81-9 4-(2-((2S,3S)-2-Acetyl-3-(tert-butyldimethylsilyloxy)pyrrolidin-1-yl)-2-oxoethyl)-2-chloro-3-methylbenzonitrile 
• 757247-90-8 C₂₃H₃₄ClN₃O₂Si 
• 757247-89-5 (2R,3R)-3-(tert-butyldimethylsilanyloxy)-N-(3-chloro-4-cyano-2-methylphenyl)-2-((S)-1-hydroxy-2-methylpropyl)pyrrolidine-1-carboxamide 
• 945469-40-9 C₂₁H₂₇F₃ClN₃O₂Si 
• 945469-39-6 C₂₁H₂₉F₃ClN₃O₃Si 
• 757247-75-9 2-chloro-4-iodo-3-methylbenzonitrile 

Relevant academic research and scientific papers

Synthetic method 5- of -4- (-1- I -3-)-(C)-(C)-ethyl-methyl-indol. (by machine translation)

To the method, the 3 - indole chromogenic 5 - substrate is obtained, by hydrolyzing the indole phenol with acetic. anhydride, under an acidic condition with acetic, anhydride to form an indole, chromogenic substrate by hydrolyzing the, indole phenol, with acetic anhydride under an acidic, condition with acetic anhydride under an acidic condition 5 - 5 . (by machine translation)

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Compounds of Formula I and the pharmaceutically acceptable salts thereof are provided as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

PYRAZOLINE DERIVATIVES AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Indoxylic acid esters as convenient intermediates towards indoxyl glycosides

Indoxylic acid methyl and allyl esters with varied halide-substitution patterns were obtained in excellent yields using a scalable route. Phase-transfer glycosylation of these key intermediates was carried out with various glycosyl halides. Subsequent mild silver-mediated decarboxylation followed by Zemplen deacetylation led to indoxyl glycosides in good overall yields. Indoxyl glycosides are well-established and widely used tools for enzyme screening and enzyme-activity monitoring. In the past, their synthesis has been difficult, so this new approach has led to a variety of useful structures. Indoxyl glycosides with varied halide-substitution patterns were synthesized using indoxylic acid esters as key intermediates. Glycosylation under phase-transfer conditions, ester cleavage, and mild decarboxylation led to the indoxyl glycosides in good yields. This approach enables access to a number of different indoxyl compounds. Copyright

PYRAZOLINE DERIVATIVES AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition

Novel efficient routes to indoxyl glycosides for monitoring glycosidase activities

A new efficient synthesis for broad access to indoxyl glycosides was developed. Indoxylic acid allyl ester linked to a sugar structure served as the key intermediate in this route. Selective ester cleavage and mild decarboxylation led to the corresponding indoxyl glycosides in good yields. This synthesis was applied for preparation of indoxyl glycosides of fucose, sialic acid, and 6′-sialyl lactose.

ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS

The invention provides well-defined aryl fluoroethyl ureas that are useful as selective alpha2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of alpha2 adrenergic receptors.

Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications

A novel series of imidazolin-2-ones were designed and synthesized as highly potent, orally active and muscle selective androgen receptor modulators (SARMs), with most of the compounds exhibiting low nM in vitro potency in androgen receptor (AR) binding and functional assays. Once daily oral treatment with the lead compound 11a (AR Ki = 0.9 nM, EC50 = 1.8 nM) for 14 days induced muscle growth with an ED50 of 0.09 mg/kg, providing approximately 50-fold selectivity over prostate growth in an orchidectomized rat model. Pharmacokinetic studies in rats demonstrated that the lead compound 11a had oral bioavailability of 65% and a plasma half-life of 5.5 h. On the basis of their preclinical profiles, the SARMs in this series are expected to provide beneficial anabolic effects on muscle with minimal androgenic effects on prostate tissue.

Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators

Pharmacokinetic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. Subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential.

Novel bicyclic compounds as modulators of androgen receptor function and method

The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X and n are defined herein.